Entrada reports Q1 net loss of $17.3M, gets EU clearance for DMD exon 44 trial, cuts workforce 20%

Entrada Therapeutics, Inc.

Net loss of $17.3M in Q1 2025 vs net income $23.5M Q1 2024; collaboration revenue fell to $20.6M from $59.1M.
EU authorization received for Phase 1/2 MAD study (ELEVATE-44-201) of ENTR-601-44; Q2 2025 initiation on track.
Additional DMD programs: ENTR-601-45 study initiation Q3 2025; ENTR-601-50 regulatory submission H2 2025.
Workforce reduced ~20% to focus on DMD clinical pipeline and key preclinical programs; cash runway into Q2 2027 ($382.5M).
Vertex-partnered VX-670 for DM1 continues enrollment in MAD portion of Phase 1/2 trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.